Expression of Myostatin Pro Domain Results in Muscular Transgenic Mice
Overview
Reproductive Medicine
Affiliations
Myostatin, a member of the TGF-beta family, negatively regulates skeletal muscle development. Depression of myostatin activity leads to increased muscle growth and carcass lean yield. In an attempt to down-regulate myostatin, transgenic mice were produced with a ribozyme-based construct or a myostatin pro domain construct. Though the expression of the ribozyme was detected, muscle development was not altered by the ribozyme transgene. However, a dramatic muscling phenotype was observed in transgenic mice carrying the myostatin pro domain gene. Expression of the pro domain transgene at 5% of beta-actin mRNA levels resulted in a 17-30% increase in body weight (P < 0.001). The carcass weight of the transgenic mice showed a 22-44% increase compared with nontransgenic littermates at 9 weeks of age (16.05 +/- 0.67 vs. 11.16 +/- 0.28 g in males; 9.99 +/- 0.38 vs. 8.19 +/- 0.19 g in females, P < 0.001). Extreme muscling was present throughout the whole carcass of transgenic mice as hind and fore limbs and trunk weights, all increased significantly (P < 0.001). Epididymal fat pad weight, an indicator of body fat, was significantly decreased in pro domain transgenic mice (P < 0.001). Analysis of muscle morphology indicated that cross-sectional areas of fast-glycolytic fibers (gastrocnemius) and fast-oxidative glycolytic fibers (tibialis) were larger in pro domain transgenic mice than in their controls (P < 0.01), whereas fiber number (gastrocnemius) was not different (P > 0.05). Thus, the muscular phenotype is attributable to myofiber hypertrophy rather than hyperplasia. The results of this study suggest that the over-expression of myostatin pro domain may provide an alternative to myostatin knockouts as a means of increasing muscle mass in other mammals.
Wetzlich B, Nyakundi B, Yang J Mol Cell Biochem. 2024; 480(3):1535-1553.
PMID: 39340593 PMC: 11842502. DOI: 10.1007/s11010-024-05120-y.
Duchenne muscular dystrophy: disease mechanism and therapeutic strategies.
Bez Batti Angulski A, Hosny N, Cohen H, Martin A, Hahn D, Bauer J Front Physiol. 2023; 14:1183101.
PMID: 37435300 PMC: 10330733. DOI: 10.3389/fphys.2023.1183101.
Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies.
Baig M, Ahmad K, Moon J, Park S, Lim J, Chun H Front Physiol. 2022; 13:876078.
PMID: 35812316 PMC: 9259834. DOI: 10.3389/fphys.2022.876078.
Hulmi J, Nissinen T, Penna F, Bonetto A Cells. 2021; 10(3).
PMID: 33671024 PMC: 7997313. DOI: 10.3390/cells10030516.
Kim J, Park K, Lee J Int J Environ Res Public Health. 2020; 17(13).
PMID: 32645967 PMC: 7369921. DOI: 10.3390/ijerph17134900.